Johnson & Johnson acquires Actelion

January 26, 2017 News BioVox

After weeks of rumors, the news was finally announced this morning. J&J is to buy Europes largest biotech company for a whopping $30 billion. The R&D division of the Swiss company will be spun out as a new company listed on the Swiss stock market.

Actelion was founded 20 years ago by ex-Roche employees and focused on rare diseases. The company currently has 4 products on the market, including blockbuster Tracleer. Tracleer is used to treat pulmonary arterial hypertension and made a turnover of 1.6 billion in the first 9 months of 2016.

Read the full press release here.

Avatar photo

With a local focus and global reach, BioVox shares insights into the Belgian life sciences ecosystem with an ever-growing global community. BioVox is a non-profit project: we are able to provide our community with free, quality content because of the generous support of Turnstone Communications and its clients. Our articles bring you hidden opportunities and exclusive insights into the latest research and industry trends!

All posts